NasdaqCM - Delayed Quote • USD
ChromaDex Corporation (CDXC)
At close: April 22 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.02 | -0.01 | -0.01 | 0.05 |
| Low Estimate | -0.03 | -0.02 | -0.03 | 0.03 |
| High Estimate | -0.01 | 0 | 0.01 | 0.09 |
| Year Ago EPS | -0.03 | -0.03 | -0.07 | -0.01 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 23.97M | 23.84M | 97.57M | 114.37M |
| Low Estimate | 23.7M | 23.6M | 97.02M | 112.2M |
| High Estimate | 24.41M | 24.2M | 98.6M | 116.5M |
| Year Ago Sales | 22.56M | -- | 83.57M | 97.57M |
| Sales Growth (year/est) | 6.30% | -- | 16.80% | 17.20% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.05 | -0.04 | -0.03 | -0.03 |
| EPS Actual | -0.03 | -0.03 | -0.01 | 0 |
| Difference | 0.02 | 0.01 | 0.02 | 0.03 |
| Surprise % | 40.00% | 25.00% | 66.70% | 100.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.02 | -0.01 | -0.01 | 0.05 |
| 7 Days Ago | -0.02 | -0.01 | -0.01 | 0.05 |
| 30 Days Ago | -0.02 | -0.01 | -0.01 | 0.05 |
| 60 Days Ago | 0 | 0 | 0 | 0.08 |
| 90 Days Ago | 0 | 0 | 0 | 0.08 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CDXC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 33.30% | -- | -- | 0.20% |
| Next Qtr. | 66.70% | -- | -- | 9.40% |
| Current Year | 85.70% | -- | -- | 4.40% |
| Next Year | 600.00% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Roth MKM: Buy to Buy | 4/9/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/11/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/10/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/5/2023 |
| Maintains | HC Wainwright & Co.: Buy | 3/13/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 2/1/2023 |
Related Tickers
VIRI Virios Therapeutics, Inc.
0.4257
-2.25%
NRSN NeuroSense Therapeutics Ltd.
1.3500
-4.93%
VTGN Vistagen Therapeutics, Inc.
4.7800
+0.42%
MAIA MAIA Biotechnology, Inc.
2.2600
+5.12%
GANX Gain Therapeutics, Inc.
3.1700
-0.31%
CDTX Cidara Therapeutics, Inc.
0.5139
-24.54%
BCAB BioAtla, Inc.
2.1800
+3.56%
TSHA Taysha Gene Therapies, Inc.
2.4600
+8.37%
ACET Adicet Bio, Inc.
2.0000
+2.56%
VIRX Viracta Therapeutics, Inc.
0.8800
+2.72%